Work

Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer

Year: 2026
Type: article
Abstract: Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7204528785
FWCI:
Cites: 50
Cited by:
Related to: 10